## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)															
1. Name and Address of Reporting Person* CARR EDWARD				2. Issuer Name and Ticker or Trading Symbol ABEONA THERAPEUTICS INC. [ABEO]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner						
(Last) (First) (Middle) 1330 AVENUE OF THE AMERICAS, 33RD FLOOR				3. Date of Earliest Transaction (Month/Day/Year) 09/12/2019							X Office	er (give title bel Chief	ow) Accounting		specify belower	N)	
(Street) NEW YORK, NY 10019				4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line)  X_Form filed by One Reporting Person  Form filed by More than One Reporting Person						
(City	Table I - Non-Derivative Securities Acqui						ired, Disposed of, or Beneficially Owned										
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, any (Month/Day/Ye.		if Code (Instr. 8			4. Securities Acquire (A) or Disposed of (I (Instr. 3, 4 and 5)		of (D)	Beneficia	ant of Securities ally Owned Following d Transaction(s)		6. Owne Form	ership of Be	7. Nature of Indirect Beneficial Ownership
				(Wolldi)	Бау/Теа		Code	V	Amour	Amount (A) or (D)		(mode 2 and 4)			or Ind (I) (Instr.	direct (In	(Instr. 4)
Abeona Therapeutics Inc. Common Stock (1)  09/12/2019			09/12/2019				A		20,00	0 A	\$ 0	20,000		D			
			Table II - I				tl	he fo	orm dis posed o	plays a o	currer eficiall	ntly valid	OMB con	spond unle trol numbe			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Yo	3A. Deemed Execution Date any	4. Transaction Code (Instr. 8)		5.		6. Datand E (Mont	te Exerc xpiratio th/Day/ <sup>1</sup>	e Exercisable securie Exercisable spiration Date h/Day/Year)  Expiration Sable Date		tle and bunt of erlying rities r. 3 and			y Do See Di or	wnership orm of erivative ecurity: irect (D) Indirect	Beneficia Ownershi (Instr. 4) D)
				Co	ode V	(A)	(D)	Exerc	isable	Jate		of Shares					
Repor	ting O	wners															

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
CARR EDWARD 1330 AVENUE OF THE AMERICAS, 33RD FLOOR NEW YORK, NY 10019			Chief Accounting Officer				

## **Signatures**

/s/ Edward Sturchio, as Attorney-in-fact	09/16/2019			
**Signature of Reporting Person	Date			

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a)
- (1) The award was granted under the Abeona Therapeutics Inc. Equity Incentive Plan and will vest 100% on March 12, 2020.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.